• Soo-Yeon Chae, Yeonju Woo, Joo-Hee Kim, Eun-Jung Kim, Byung-Kwan Seo, Yong-Hyeon Baek, Seong-Sik Park, and Won-Suk Sung.
• College of Korean Medicine, Dongguk University Graduate School, Seoul, Republic of Korea.
• Medicine (Baltimore). 2022 Mar 25; 101 (12): e29174e29174.

BackgroundRheumatoid arthritis (RA) is a common chronic autoimmune disease that contributes to progressive disability, systemic complications, higher mortality, and societal burden. Typical symptoms of RA include symmetrical pain and swelling in multiple joints, morning stiffness, and elevated levels of erythrocyte sedimentation rate, C-reactive protein, and rheumatoid factor. The representative treatment for RA is medication, including disease-modifying antirheumatic drugs, glucocorticoids, and nonsteroidal anti-inflammatory drugs. However, these medications are not yet curative nor preventative and are associated with several adverse effects, leading to their discontinuation. Recent articles reported that Simiao Xiaobi decoction (SXD) could relieve the symptoms of RA by clinical trial and experimental study, but an evidence-based review on the effectiveness and safety of SXD on RA has not yet been provided.MethodsSearching for randomized controlled trials on the use of SXD for RA will be performed by using multiple electronic databases, manual search, and contacting the authors by e-mail if needed. Studies will be selected according to the predefined criteria and the data collected on study participants, interventions, control groups, outcome measurements, their results, adverse events, and risk of bias will be summarized. The primary outcome will be the disease activity score (including effective rate, swollen joint count, tender joint count, and morning stiffness), and the secondary outcomes will be blood tests (including erythrocyte sedimentation rate, C-reactive protein, and rheumatoid factor) and adverse events. We will use Review Manager software to perform a meta-analysis, the Cochrane Collaboration "risk of bias" tool for assessing the risk of bias, and grades of recommendation, assessment, development and evaluation for the determination of the quality of evidence.Trial Registration Numberhttps://inplasy.com; INPLASY202230026.ResultsWe are going to investigate the effectiveness and safety of SXD for RA.ConclusionThis study will provide reliable evidence on whether SXD is effective on RA.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

49 keywords...

hide…